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Abstract The first mouse mutation associated with a herita-
ble defect in embryonic mammary gland development was
Extratoes. It represents a functional null-mutation of the gene
encoding Gli3, which is best known as a transcription factor
mediating canonical Hedgehog (Hh) signaling. Here we re-
view the roles of Hh and Gli proteins in murine embryonic
mammary development. We propose that an off-state for Hh
signaling, mediated by Gli3-repressor, is determinant for in-
duction of a mammary instead of hair follicle fate in the trunk
surface ectoderm.
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FGF Fibroblast Growth Factor
FGFR2b FGF Receptor 2-IIIb
Gli Glioma-associated oncogene
Gli1A,Gli2A, Gli3A Gli1, Gli2 or Gli3 transcriptional
activators






MR Mammary rudiment (pair)






Xt-J, XtJ Extratoes mutation (mouse) identified
at The Jackson Laboratory
Introduction
Mouse embryos form five pairs of mammary rudiments
(MRs). Their formation is preceded by the formation of
three Wnt10b-expressing mammary streaks in the axilla,
inguen, and in between forelimb and hindlimb respectively
around embryonic day (E) 10.5. These streaks fuse into one
continuous mammary line (ML) on each flank by E11.5, on
which MRs develop in asynchronous fashion and not in
numerical sequence, with MR1 in the axilla; MR2, MR3
and MR4 on the flank; and MR5 in the inguen [1].
The Hedgehog (Hh) pathway was among the first signal-
ing cascades tested for a role in murine mammogenesis, but
is not required for it [2, 3]. Nonetheless, Extratoes (Xt) mice,
which harbor a spontaneous, functional null-mutation for
the transcription factor Gli3, exhibit multiple defects in
prenatal mammary development [4–7].
Given the role of Gli3 in Hh signaling, we provide a
brief overview of Hh signaling and Gli transcription
factors, followed by their functions in mammogenesis
in mouse embryos.
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Signal Transduction via Hedgehog and Gli Proteins
Mammals possess three orthologues of the Drosophila seg-
ment polarity gene Hedgehog; Sonic hedgehog (Shh),
Indian hedgehog (Ihh), and Desert hedgehog (Dhh) [8, 9].
While embryonic expression and function of Dhh is restrict-
ed to spermatogenesis and Schwann cells, Shh and Ihh are
widely expressed and encode secreted morphogens with
well-known roles for Shh in neural tube, limb and somite
development and for Ihh in chondrogenesis [10, 11].
In canonical Hh signaling, Hh molecules bind their
twelve-transmembrane receptor Patched1 (Ptch1) or Ptch2.
Ptch then derepresses the seven-transmembrane protein
Smoothened (Smo), which becomes activated. Through in-
tracellular signaling complexes -whose components have
not been studied in embryonic mammary development and
are thus not described here- Smo activation converges on the
Gli family of Krüppel-type zinc-finger transcription factors,
comprising Gli1, Gli2 and Gli3. Gli1 is expressed when Hh
signaling is active, and encodes the transcriptional activator
Gli1A. Gli2 and Gli3 can be expressed in the absence of Hh
signaling, in which case their protein products are cleaved to
render transcriptional repressors (Gli2R, Gli3R). Gli2 re-
quires less active Hh signaling than Gli3 to remain
uncleaved and function as a transcriptional activator
(Gli2A, Gli3A). Among Gli transcriptional targets are Gli1
and Ptch1, which provide regulatory feedback loops for Hh
signaling [12, 13].
Recently, deviations from this canonical paradigm have
been discovered [14]. They need further exploration, but
certainly point to three additional, “non-canonical” signal-
ing scenarios: 1) Signaling involving Hh pathway compo-
nents independently of Gli-mediated transcription, such as
Shh-mediated ERK activation in mammary epithelial cells
without Smo-activation [15]; 2) Direct interaction of Hh
signalling components with other molecular pathways; po-
tentially relevant for mammogenesis is the role of Wnt
signaling in expression and function of Gli proteins [16],
and 3) “Non-contiguous” or “atypical” interaction of core
Hh pathway components with each other.
Pleiotropic Functions of Gli3 in Mammary Development
Studies of the role of Hh signaling components in
mammogenesis began in the late 1960’s, when D.R.
Johnson identified and characterized a mouse strain which
he named Extra-toes (Xt), after the prominent polydactyly in
all four paws of heterozygotes [4]. In E13 embryos homo-
zygous for this spontaneous, semi-dominant mutation, he
also found a reduced number of MRs between the forelimb
and hindlimb. Because his wild type control had a supernu-
merary MR near MR3, he concluded that “the number of
nipples visible in Xt/Xt mice at this stage is reduced from
four to two pairs, the most anterior and posterior ones
persisting” [4]. Note that Johnson was mistaken in three
aspects: 1) what he referred to as nipples were in fact
mammary buds, which precede nipple formation [17]; 2)
had he taken a proper control, he would have concluded that
only one MR (MR3) was missing on the flank; 3) had he
known that wild-types also form MRs behind the forelimb
(MR1) and hindlimb (MR5), he would have noticed an
absence of MR5 in Xt/Xt embryos [5–7, 18]. Additional
Xt/Xt mammary defects are described below.
At The Jackson Laboratory arose a spontaneous mouse
mutant, named XtJ because it phenocopies Johnson’s Xt
mutant [19]. XtJ mice carry a 51.5 kb deletion downstream
of nucleotide 1670 of Gli3, including the DNA-binding zinc
fingers and thus abolishing both Gli3A and Gli3R functions
[19–21], without loss of other known functional sequences.
These renamed Gli3Xt-J mice represent a good model for the
human Greig cephalopolysyndactyly syndrome (GCPS),
which can be a sporadic or inherited trait, caused by hetero-
zygous loss-of-function mutations of the GLI3 gene. The
syndrome is characterized by polysyndactyly of hands and
feet, hypertelorism, and skull abnormalities including cra-
niosynostosis at variable penetrance [19, 22][OMIM
165240, 175700], the latter seen in mice only when homo-
zygous mutant [23].
While no mammary phenotypes have been reported for
GCPS patients and Gli3Xt-J/+ mouse mutants, Gli3Xt-J/Xt-J
embryos fail to induce MR3 and MR5 [5–7, 18].
Moreover, their MR2 and MR4 are hypoplastic; MR2 pro-
trudes in females [18] (compare Fig. 1t with 1l), resembling
MRs of wild-type male embryos [17], and also exhibits
impaired branching morphogenesis; while MR1 is hardly
affected [18]. The XtJ mutation thus exemplifies that all
mammary glands are different and can develop inter-
independently [24]. The question then arises via which
molecular mechanisms and tissue-interactions Gli3 regu-
lates formation and development of MR2-5.
Prior to and at the time of ML and MR formation, Gli3 is
not expressed in the surface ectoderm [5], from which the
MRs derive [25], but is expressed in the limb mesenchyme,
and in the somites in the region between fore- and hindlimbs
[5] (Fig. 1c). Given the earlier implications of somitic in-
volvement in the establishment of the mammary streak
along the flank and in MR induction [1, 7], the somitic
Gli3 expression was of interest. Indeed, the ventral elonga-
tion of the somites including expression of Gli3 in all
thoracic and lumbar somites, and Fibroblast growth factor
(Fgf)10 in thoracic somites #12 to #18, determines the
position of the ML on the dorso-ventral body axis [5]. The
absence of MR3 in Gli3Xt-J/Xt-J embryos [5] is due to reduc-
tion of somitic Fgf10 expression, in particular the relatively
high Fgf10 expression in somite #15 underlying MR3 [5].
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Fig. 1 Expression patterns of Gli1, Gli2 and Gli3, and models of
tissue- and molecular interactions involving Gli3 in mammary develop-
ment. a–q Cross-sections of wild-type embryos and (r–w) Gli3Xt-J/Xt-J
embryos at E11.5-E13.5 hybridized with 35S-labeled RNA-probes for
Gli1, Gli2 and Gli3. Magnification of r-w is twice that of a–q. Insets in
t’ and u’ present wild-type MR2 from l’ respectively m’ at the same
magnification. MRs are indicated by number. Black arrow in a–c in-
dicates emergingMR3 at E11.5.White arrowheads in r’, t’ s’ and u’ point
to MM expression. x Cartoon of a lateral view of a mouse embryo.
Between E10.5 and E11.5 Gli3 is expressed in the limb buds and all
somites (outlined in gray and numbered). Gray shades represent
overlapping in expression with Fgf10, the intensity positively correlating
with level of Fgf10 expression. Note the proximity of the overlapping
somitic expression to MR3 and MR2, and overlapping limb mesenchy-
mal expression toMR1,MR2,MR4 andMR5.MR1 andMR5 are hidden
behind the limbs. y Model exclusively for formation of MR3: See main
text for explanation. zModel for Gli3-mediated repression of Gli1 in the
ME (bud shape) and contiguous MM (darker shade of gray surrounding
mammary bud), based on expression data in panels a–w and in [5, 6]. In
the absence of Gli3, Gli1 is misexpressed in the MM of MR1, MR2 and
MR4, indicating Gli3R normally represses Gli1 expression. Whether this
occurs tissue-autonomously (intact block arrow) or via tissue interactions
(broken block-arrow) remains unclear. Abbreviations: li: liver, r: rib
primordium, st: stomach, wt: wild-type
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As MR2 is located above somite #12 [5], reduced somitic
Fgf10 expression may be involved in impaired development
of MR2 as well.
It is most likely that somitic Gli3 indirectly activates somitic
Fgf10 independent of Shh signaling ([5] and references there-
in). Somitic FGF10 may reach and activate the ectodermal
FGFR2b via diffusion and/or transportation by dermal precur-
sor cells that delaminate from the somites. This cascade leads
to ectodermal cell elongation,Wnt10b marker expression, and
canonical Wnt signaling as required for ML and MR forma-
tion, but only at the level of MR3 [5], and possibly MR2.
These insights finally gave some molecular explanation for the
capacity of the dermal mesenchyme to induce MR formation
as recognized four decades earlier [25–27].
However, at the level of MR4 and MR5, Fgf10 is not
expressed in the somites. Given that null mutants for either
Gli3 or Fgf10 fail to induce MR5 and both genes are
expressed in the adjacent limb mesenchyme [5] (Fig. 1x), it
is tempting to speculate that an epistatic interaction between
these molecules may also exist in the limb mesenchyme and
be required for induction of MR5. The compromised induc-
tion of MR2 and MR4 in the absence of Gli3 can perhaps be
attributed to Gli3-independent residual expression of Fgf10
and other genes in the thoracic somites and limbmesenchyme.
The cellular functions of Gli3 during early mammary
growth and morphogenesis are fourfold, and the same in all
MRs [18]: downregulation of 1) cell proliferation and 2) cell
apoptosis in epithelial cells of the ML and MRs; 3) mediation
of ectodermal cell recruitment into MRs, which contributes to
MR growth until at least E14.5; 4) hypertrophy of the
basal/peripheral cells of the ME, which provides a large
proportion of the growth between E12.5 and E13.5 [18].
While similar regulatory functions for Gli3 have been identi-
fied in other cell types (references in [18]), it remains to be
investigated how Gli3 mediates so many distinct effects in the
same cell population; and whether these epithelial effects rely
on Gli3 expression prior to mammary induction, on cell-
autonomous Gli3 function in the ME, or via tissue-
interactions with and Gli3 expression in the MM (Fig. 1z).
Mammogenesis Does not Require Gli1 and Gli2,
but Only Gli3R
At E11.5, the somites also express Gli2, but not Gli1
(Fig. 1a, b) [6]. Expression of Gli genes in the surface
ectoderm or mammary tissues is arguable at E12.5, except
for notable Gli3 expression in MR5 (Fig. 1d–k) as con-
firmed by RNA-profiling [18]. By E13.5, Gli3 and Gli2
are convincingly expressed in overlap in the ectoderm,
mammary epithelium (ME) and mammary mesenchyme
(MM) (Fig. 1m,n,p,q), the latter confirmed for Gli3 by
RNA-profiling [18] and immunohistochemistry [6]. Thus,
the initial growth defects of Gli3Xt-J/Xt-J MR2 and MR4 at
E11.5 could subsequently be compounded by the lack of
Gli3 in any of the tissue compartments.
Although Gli2 and Gli3 overlap in expression, homozy-
gousGli2-null mutants have nomammary induction defect [6,
28]. Neither have Gli1-null, Gli2lkni/+ or Gli2lkn/lkni mutants
which express Gli1A from the endogenous Gli2 promoter [6].
However, removing one Gli3 allele in Gli2lkni/lkni embryos
abolishes induction of MR3 and MR5 as in Gli3Xt-J/Xt-J em-
bryos. Moreover, Gli1 is misexpressed in the MM of MR2 in
E13.5Gli3Xt-J/Xt-J embryos (Fig. 1t). The highGli1 expression
in MR1 and MR4 at E13.5 (Fig. 1r, v) may also reflect
misexpression in the MM, similar to such misexpression
reported at E14.5 [6]. Together, these data indicate that Gli3
acts as Gli3R during MR formation [6] (Fig. 1y, z), and is the
only Gli family member with functional relevance for embry-
onic mammary development, by repressingGli1 transcription,
and antagonizing Gli2A function [6]. Moreover, these data
indicate that canonical Hh signaling needs to be in an off-
state to allow mammogenesis [6], at least at the positions of
MR3 and MR5.
Mammogenesis Requires Absence of Hh Signaling,
Likely to Prevent Acquisition of a Hair Follicle Fate
The above-described repressor function of Gli3 and absence
of Shh, Ihh, Gli1 and Ptc1 expression in the surface ectoderm
or dermal mesenchyme at the time of ML and MR induction
[6] (our unpublished data and Fig. 1a), explain why Shh−/−
and Ihh−/− mutant mice have no mammary induction defect
[2, 3]. All together, these data indicate Hh signaling is not
required for induction of any of the fiveMRs.While normally,
Shh, Ihh and Ptc1 are expressed in theME fromE12.5 onward
and in postnatal stages [3], the normal outgrowth of
transplanted E12.5 Shh−/− and Ihh−/− ME in cleared wild-
type mammary fat pads or under the kidney capsule, indicates
that epithelial Hh signaling or mesenchymal Shh is not either
required during later embryonic and postnatal stages [2].
Interestingly, activating components of the Hh signaling
cascade become expressed in the surface ectoderm and ME
only after the formation of MR, but prior to hair follicle
formation [3]. Moreover, Shh is required for hair follicle
development [2, 3]. We therefore propose that the off-state
of Hh signaling is a discriminatory factor for the choice of a
skin appendage between mammary and either hair or non-
mammary fate, and that therefore MRs must develop prior
to hair follicle formation, i.e. prior to activation of Hh
signaling in the trunk ectoderm [29, 30]. Such a decisive
role for Hh signaling appendage fate requires further inves-
tigation, but seems to be confirmed by the glandular appear-
ance of hair follicles when Hh signaling in the skin is
ablated in K14Cre;Smofl/fl embryos [31].
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Conclusion and Perspectives
Gli3 function is critical for embryonic development of
MR2-5; in particular GliR-mediated repression of canonical
Hh signaling is critical for induction of MR3 and MR5. Its
variable requirement for the five MRs in mouse gives per-
haps some insight in mechanisms underlying the variation in
number of mammary glands among mammalian species. For
example, MR3 requires somitic Gli3 as the earliest known
effector in a cascade involving FGF10/FGFR2b and subse-
quent Wnt signaling (Fig. 1y), but other tissue-interactions
and perhaps molecular mechanisms act downstream of Gli3 in
early development of other MRs, and remain to be elucidated.
Examples of additional interesting avenues for investigation
pertain to possible interactions with other important mesen-
chymal factors in MR3 formation (e.g. Nrg3, Tbx3, or Raldh2
that mediates retinoic acid signaling) [32–34] (Fig. 1y);
whether the sustained protrusion of MR2 in Gli3Xt-J/Xt-J em-
bryos bears any mechanistic similarity to the protrusion of
MRs in wild-type males; and whether Gli3 is involved in non-
canonical Hh signaling in mammogenesis.
Given the many molecular similarities between embry-
onic mammary development and mammary/breast tumors
[35, 36], it is of interest whether GLI3 plays a role in breast
cancer. It is noteworthy that GLI(1) was discovered as an
oncogene, and like GLI2 and SHH, is upregulated in various
cancers [13]. HH signaling is considered a therapeutic target
for breast cancer, as GLI(1) upregulation predicts a poor
prognosis for estrogen receptor negative or triple negative
breast cancers [37–39]. Yet, GLI3 is seldom reported in
association with cancer [13]. In absolute number and relative
Gli1, only few somatic mutations in Gli3 have been found in
breast cancer samples [COSMIC database, Sanger institute]. It
would be of interest to determine whether these Gli3 muta-
tions relate to Gli1 upregulation, and whether they have any
diagnostic or prognostic value.
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